Skip to content

Clinical outcomes for patients diagnosed with renal cancer and caval thrombus involvement considering surgery

Clinical outcomes for CAVAL THROMbus involved Renal Cell Cancer (Imperial Renal 1 – CAVALThromb): a prospective, multicentre registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN23209146
Enrollment
20
Registered
2025-07-07
Start date
2025-01-20
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma with inferior vena cava thrombus involvement Cancer

Interventions

IR1-CAVALThromb is a prospective, multicenter, registry study. The researchers plan to invite several centers to the register. They will collect data on patients who undergo radical nephrectomy with c

Sponsors

Imperial College Healthcare NHS Trust
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Any person over the age of 18 years referred to a supra-regional MDT following a new diagnosis of suspected caval thrombus involved renal cancer

Exclusion criteria

Exclusion criteria: 1. Age under 18 years old 2. Patients who are found to have no evidence of caval thrombus on dedicated tertiary imaging

Design outcomes

Primary

MeasureTime frame
Standard operating procedure (SOP) for radical nephrectomy and caval thrombectomy surgery generated using the RAND/University of California at Los Angeles (UCLA) appropriateness method, completed once the last patient recruited has reached 3-month follow-up

Secondary

MeasureTime frame
1. Morbidity of patients undergoing surgery and those who do not undergo immediate operative management assessed using the Clavien-Dindo Classification and/or the common terminology criteria for adverse events (CTCAEv5.0) at 3-month follow-up 2. Patient-reported outcome measures and health-reported quality-of-life measured using: 2.1. Clinical frailty score at baseline and 3-month follow-up 2.2. EORTC QLQ-F17 and EQ-5D-5L validated questionnaire at baseline and 3-month follow-up 3. Surgical complications assessed using the Clavien-Dindo Classification of patients at 3 months follow-up 4. Key recommendations for optimal patient care and objectives for further research developed using the RAND/University of California at Los Angeles (UCLA) appropriateness method, completed once the last patient recruited has reached 3-month follow-up

Countries

England, United Kingdom

Contacts

Public ContactMartin J. Connor
m.connor@imperial.ac.uk+44 (0)20 3311 1234

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026